الفهرس 
INTRODUCTION TO LIVER VASCULAR DISEASESOnly 14 pages are availabe for public view
 |  | from | 283 |  |  |
| | | from | 283 | | |
Abstract
1. Early detection of hepatic diseases (Viral, auto-immune, metabolic drug induced or fatty liver) through the usual screening procedures for the high risk group.
2. Being more vascular oriented when dealing with CLD patient to prevent the long term deterioration and morbidity.
3. Early treatment of the injurious stimuls relifes the inflammatory process of the liver, improving the long term survival.
4. Surgical and radiologic intervention should always be considered according to the Risk/benefit.
5. Liver transplantation will solve lot of hepatic conditions.
6. Considering hemodynamic abnormalities (Decreased arterial supply, decreased venous drainange) in cases of recent or rapidly deteriorating liver disease.
7. Concerning the Investigations done for hepatic patients:
a. General examination.
b. Vital data and fluid charts.
c. Lab. Investigations:
i. Routine labs.
ii. Arterial blood gasses.
iii. Serum electrolytes and urinary sodium.
iv. Investigations for hypercoagulable state:
- Factor V ladin
- Anti-phospholipid Ab.
- Anti-thrombin III
- Protien C
- Protien S
d. Radiologic investigations:
i. Abdominal U/S with Doppler flow study should be a routine examination if available.
ii. Chest X-Ray.
iii. CT, MRI, Arteriography, Venography and Portography should be done only for the suspected cases according to the Cost/benefit for the patient.
iv. Contrast induced echocardiography and Pulmonary angiography for the suspected cases of hepatopulmonary syndrome.
e. Other investigations:
i. Upper GI endoscopy.
ii. Liver biopsy.
iii. Pulmonary function tests.
8. Concerning the drug therapy, the guide lines in the management of each disease should be followed strictly in order to optimize the treatment for the patients.
9. Being more oriented with the use of thrombolytic therapy and anticoagulants.
10. Follow up the progress in the studies and trials done on various promising new drugs such as:
a. Ursodeoxycholic acid, Interlukin 10 and Anti-oxidants as NAC and silymarin for thier antifibrogenic and anti-inflamatory action decreasing the inflammatory process.
b. Endotheline receptor antagonists (Tezosentan) which has antifibrogenic activity and in the same time less hepatotoxic than the (Bozentan)
c. Pentoxifylline which inhibit the HSC proliferation and collagen synthesis.
d. Satavaptan with its effect in correcting hyponatremia and decreasing the incidence of hepatic encephalopathy.
e. Fausidil which is used in treatment of PHTN as it lowers the portal vascular resistance , increasing portal blood flow, decreasing portal pressure without reducing arterial pressure.
f. Defibrotide in the treatment of VOD.
g. Terlipressin in the treatment of Hepatorenal syndrome.
h. Epoprostenol, sildenafil and Iloprost in the treatment of PPHTN.